Prestige Consumer Healthcare (NYSE:PBH) Updates FY 2025 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 4.500-4.500 for the period, compared to the consensus earnings per share estimate of 4.440. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on PBH. DA Davidson raised their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a report on Friday. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a research report on Monday, December 9th. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Friday, January 24th. Finally, Canaccord Genuity Group lifted their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $92.50.

Prestige Consumer Healthcare Stock Performance

Shares of Prestige Consumer Healthcare stock traded up $0.01 during trading on Friday, hitting $87.36. 247,604 shares of the stock were exchanged, compared to its average volume of 304,087. The stock’s fifty day moving average is $79.19 and its 200 day moving average is $75.34. The stock has a market cap of $4.32 billion, a PE ratio of 21.27, a P/E/G ratio of 2.15 and a beta of 0.50. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. Prestige Consumer Healthcare has a 12 month low of $60.00 and a 12 month high of $88.36.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. As a group, sell-side analysts anticipate that Prestige Consumer Healthcare will post 4.46 EPS for the current year.

Insider Activity at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, insider William P’pool sold 8,987 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total transaction of $735,585.95. Following the sale, the insider now owns 20,058 shares in the company, valued at approximately $1,641,747.30. The trade was a 30.94 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the transaction, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at $26,510,635.20. This represents a 3.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,810 shares of company stock valued at $3,187,300 over the last 90 days. 1.60% of the stock is currently owned by corporate insiders.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.